Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)Elizabeth Finger, Adam L. Boxer, Ging‐Yuek Robin Hsiung et al.|Alzheimer s Research & Therapy|2018Cited by 35
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trialKristy Coleman, Elizabeth Finger, Scott Berry et al.|The Lancet Neurology|2025Cited by 17